Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru

Clinical Infectious Diseases

Volumn 46, Issue 2, 2008, Pages 223-231

  Llanos Cuentas, Alejandro ^a   Tulliano, Gianfranco ^a   Araujo Castillo, Roger ^a   Miranda Verastegui, Cesar ^a   Santamaria Castrellon, Giovanna ^c   Ramirez, Luis ^a   Lazo, Marcela ^a   De Doncker, Simonne ^d   Boelaert, Marleen ^d   Robays, Jo ^d   Dujardin, Jean Claude ^d   Arevalo, Jorge ^a,b   Chappuis, Francois ^e  

^a INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

^b UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^c Hospital Dr Luis Fábrega   (Panama)

^d INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

STIBOGLUCONATE SODIUM;

ADOLESCENT; ADULT; ARTICLE; CASE CONTROL STUDY; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE DURATION; DRUG TREATMENT FAILURE; EPITHELIZATION; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LEISHMANIA; LEISHMANIA BRAZILIENSIS; LEISHMANIA PERUVIANA; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PARASITE ISOLATION; PERU; PRIORITY JOURNAL; REINFECTION; RISK ASSESSMENT; RISK FACTOR; SKIN EPITHELIUM; SKIN LEISHMANIASIS; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; WOUND CLOSURE;

ADOLESCENT; ADULT; AGE FACTORS; ANIMALS; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; CASE-CONTROL STUDIES; CHILD; FEMALE; HUMANS; LEISHMANIA; LEISHMANIASIS, CUTANEOUS; MALE; PERU; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT FAILURE;

EID: 39449105765     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/524042     Document Type: Article

References (64)

1. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg 2001; 95:239-43.
2. Croft AM, Lestringant GG, Baker BC. Cutaneous leishmaniasis following military deployment to Iraq [in French]. Med Trop (Mars) 2006; 66:185-8.
3. Sanders JW, Putnam SD, Frankart C, et al. Impact of illness and noncombat injury during Operations Iraqi Freedom and Enduring Freedom (Afghanistan). Am J Trop Med Hyg 2005; 73:713-9.
4. Weina PJ, Neafie RC, Wortmann G, Polhemus M, Aronson NE. Old world leishmaniasis: an emerging infection among deployed US military and civilian workers. Clin Infect Dis 2004; 39:1674-80.
5. Collin S, Davidson R, Ritmeijer K, et al. Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clin Infect Dis 2004; 38:612-9.
6. Schwartz E, Hatz C, Blum J. New World cutaneous leishmaniasis in travellers. Lancet Infect Dis 2006; 6:342-9.
7. Profeta da Luz ZM, Pimenta DN, Cabral AL, Fiuza VO, Rabello A. Leishmaniasis urbanization and low diagnosis capacity in the metropolitan region of Belo Horizonte [in Portuguese]. Rev Soc Bras Med Trop 2001; 34:249-54.
8. Knudsen AB. Vector-borne disease problems in rapid urbanization: new approaches to vector control. Geneva: World Health Organization, 1992.
9. Antinori S, Gianelli E, Calattini S, Longhi E, Gramiccia M, Corbellino M. Cutaneous leishmaniasis: an increasing threat for travellers. Clin Microbiol Infect 2005; 11:343-6.
10. Cardenas R, Sandoval CM, Rodriguez-Morales AJ, Franco-Paredes C. Impact of climate variability in the occurrence of leishmaniasis in northeastern Colombia. Am J Trop Med Hyg 2006; 75:273-7.
11. Davies CR, Reithinger R, Campbell-Lendrum D, Feliciangeli D, Borges R, Rodriguez N. The epidemiology and control of leishmaniasis in Andean countries. Cad Saude Publica 2000; 16:925-50.
12. Calvopina M, Armijos RX, Hashiguchi Y. Epidemiology of leishmaniasis in Ecuador: current status of knowledge - a review. Mem Inst Oswaldo Cruz 2004; 99:663-72.
13. Llanos-Cuentas A. The importance of risk factors in the control of leishmaniasis: report of the Scientific Working Group for Leishmaniasis. Geneva: Special Programme for Research and Training in Tropical Diseases-World Health Organization, 2004.
14. Dirección General de Epidemiologia. Anuario del sistema de vigilancia epidemiológica. Lima, Perú: Ministerio de Salud, 2002.
15. Lucas CM, Franke ED, Cachay MI, et al. Geographic distribution and clinical description of leishmaniasis cases in Peru. Am J Trop Med Hyg 1998; 59:312-7.
16. Llanos-Cuentas EA, Marsden PD, Cuba CC, Barreto AC, Campos M. Possible risk factors in development of mucosal lesions in leishmaniasis. Lancet 1984; 2:295.
17. Machado-Coelho GL, Caiaffa WT, Genaro O, Magalhaes PA, Mayrink W. Risk factors for mucosal manifestation of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 2005; 99:55-61.
18. Jones TC, Johnson WD Jr, Barretto AC, et al. Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis braziliensis. J Infect Dis 1987; 156:73-83.
19. Lawn SD, Armstrong M, Chilton D, Whitty CJ. Electrocardiographic and biochemical adverse effects of sodium stibogluconate during treatment of cutaneous and mucosal leishmaniasis among returned travellers. Trans R Soc Trop Med Hyg 2006; 100:264-9.
20. Oliveira-Neto MP, Schubach A, Mattos M, Goncalves-Costa SC, Pirmez C. A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years). Am J Trop Med Hyg 1997; 57:651-5.
21. Armijos RX, Weigel MM, Calvopina M, Mancheno M, Rodriguez R. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis. Acta Trop 2004; 91:153-60.
22. Soto J, Toledo J, Vega J, Berman J. Short report: efficacy of pentavalent antimony for treatment of Colombian cutaneous leishmaniasis. Am J Trop Med Hyg 2005; 72:421-2.
23. Llanos Cuentas EA, Cuba CC, Barreto AC, Marsden PD. Clinical characteristics of human Leishmania braziliensis braziliensis infections. Trans R Soc Trop Med Hyg 1984; 78:845-6.
24. Miranda-Verastegui C, Llanos-Cuentas A, Arevalo I, Ward BJ, Matlashewski G. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clin Infect Dis 2005; 40:1395-403.
25. Soto J, Fuya P, Herrera R, Berman J. Topical paromomycin/ methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study. Clin Infect Dis 1998; 26:56-8.
26. Mayrink W, Botelho AC, Magalhaes PA, et al. Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment. Rev Soc Bras Med Trop 2006; 39:14-21.
27. Romero GA, Guerra MV, Paes MG, Macedo VO. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate. Am J Trop Med Hyg 2001; 65:456-65.
28. Palacios R, Osorio LE, Grajalew LF, Ochoa MT. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species. Am J Trop Med Hyg 2001; 64:187-93.
29. Rodrigues AM, Hueb M, Santos TA, Fontes CJ. Factors associated with treatment failure of cutaneous leishmaniasis with meglumine antimoniate [in Portuguese]. Rev Soc Bras Med Trop 2006; 39:139-45.
30. Navin TR, Arana BA, Arana FE, Berman JD, Chajon JF. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992; 165:528-34.
31. Yardley V, Ortuno N, Llanos-Cuentas A, et al. American tegumentary leishmaniasis: is antimonial treatment outcome related to parasite drug susceptibility? J Infect Dis 2006; 194:1168-75.
32. Rojas R, Valderrama L, Valderrama M, Varona MX, Ouellette M, Saravia NG. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. J Infect Dis 2006; 193:1375-83.
33. Arevalo J, Ramirez L, Adaui V, et al. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis. J Infect Dis 2007; 195:1846-51.
34. Tobie EJ, von Brand T, Mehiman B. Cultural and physiological observations on Trypanosoma rhodesiense and Trypanosoma gambiense: 1949. J Parasitol 2001; 87:714-7.
35. Meredith SE, Zijlstra EE, Schoone GJ, et al. Development and application of the polymerase chain reaction for the detection and identification of Leishmania parasites in clinical material. Arch Inst Pasteur Tunis 1993; 70:419-31.
36. Rodgers MR, Popper SJ, Wirth DF. Amplification of kinetoplast DNA as a tool in the detection and diagnosis of Leishmania. Exp Parasitol 1990; 71:267-75.
37. Davies CR, Llanos-Cuentas EA, Sharp SJ, et al. Cutaneous leishmaniasis in the Peruvian Andes: factors associated with variability in clinical symptoms, response to treatment, and parasite isolation rate. Clin Infect Dis 1997; 25:302-10.
38. Andersen EM, Cruz-Saldarriaga M, Llanos-Cuentas A, et al. Comparison of meglumine antimoniate and pentamidine for Peruvian cutaneous leishmaniasis. Am J Trop Med Hyg 2005; 72:133-7.
39. Costa JM, Vale KC, Franca F, et al. Spontaneous healing of leishmaniasis caused by Leishmania viannia braziliensis in cutaneous lesions [in Portuguese]. Rev Soc Bras Med Trop 1990; 23:205-8.
40. Guglietta S, Beghetto E, Spadoni A, Buffolano W, Del Porto P, Gargano N. Age-dependent impairment of functional helper T cell responses to immunodominant epitopes of Toxoplasma gondii antigens in congenitally infected individuals. Microbes Infect 2007; 9:127-33.
41. Saenz B, Ruiz-Garcia M, Jimenez E, et al. Neurocysticercosis: clinical, radiologic, and inflammatory differences between children and adults. Pediatr Infect Dis J 2006; 25:801-3.
42. Lewinsohn DA, Gennaro ML, Scholvinck L, Lewinsohn DM. Tuberculosis immunology in children: diagnostic and therapeutic challenges and opportunities. Int J Tuberc Lung Dis 2004; 8:658-74.
43. Cruz A, Rainey PM, Herwaldt BL, et al. Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate. J Infect Dis 2007; 195:602-8.
44. Davies CR, Llanos-Cuentas EA, Pyke SD, Dye C. Cutaneous leishmaniasis in the Peruvian Andes: an epidemiological study of infection and immunity. Epidemiol Infect 1995; 114:297-318.
45. Sosa-Estani S, Segura EL, Gomez A, et al. Cutaneous leishmaniasis in northern Argentina: identification of risk factors in a case-cohort study of three municipalities in Salta [in Portuguese]. Rev Soc Bras Med Trop 2001; 34:511-7.
46. Martins LM, Rebelo JM, dos Santos MC, Costa JM, da Silva AR, Ferreira LA. Eco-epidemiology of cutaneous leishmaniasis in Buriticupu, Amazon region of Maranhao State, Brazil, 1996-1998 [in Portuguese]. Cad Saude Publica 2004; 20:735-43.
47. Ampuero J, Urdaneta M, Macedo Vde O. Risk factors for cutaneous leishmaniasis transmission in children aged 0 to 5 years in an endemic area of Leishmania (Viannia) braziliensis [in Spanish]. Cad Saude Publica 2005; 21:161-70.
48. Machado P, Araujo C, Da Silva AT, et al. Failure of early treatment of cutaneous leishmaniasis in preventing the development of an ulcer. Clin Infect Dis 2002; 34:E69-73.
49. Belkaid Y, Mendez S, Lira R, Kadambi N, Milon G, Sacks D. A natural model of Leishmania major infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity. J Immunol 2000; 165:969-77.
50. Rocha PN, Almeida RP, Bacellar O, et al. Down-regulation of Th1 type of response in early human American cutaneous leishmaniasis. J Infect Dis 1999; 180:1731-4.
51. Belkaid Y, Hoffmann KF, Mendez S, et al. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 2001; 194:1497-506.
52. + T cells in skin lesions of patients with cutaneous leishmaniasis exhibit phenotypic and functional characteristics of natural regulatory T cells. J Infect Dis 2006; 193:1313-22.
53. + regulatory T cells in reactivation of persistent leishmaniasis and control of concomitant immunity. J Exp Med 2004; 200:201-10.
54. + regulatory T cells control Leishmania major persistence and immunity. Nature 2002; 420:502-7.
55. + regulatory T cells in Leishmania infection. Expert Opin Biol Ther 2003; 3:875-85.
56. Cupolillo E, Momen H, Grimaldi G Jr. Genetic diversity in natural populations of New World Leishmania. Mem Inst Oswaldo Cruz 1998; 93:663-8.
57. Cupolillo E, Brahim LR, Toaldo CB, et al. Genetic polymorphism and molecular epidemiology of Leishmania (Viannia) braziliensis from different hosts and geographic areas in Brazil. J Clin Microbiol 2003; 41:3126-32.
58. Garcia AL, Kindt A, Llanos A, et al. American tegumentary leishmaniasis: antigen-gene polymorphism, taxonomy and clinical pleomorphism. Infect Genet Evol 2005; 5:109-16.
59. Rotureau B, Ravel C, Nacher M, et al. Molecular epidemiology of Leishmania (Viannia) guyanensis in French Guiana. J Clin Microbiol 2006; 44:468-73.
60. Silveira FT, Lainson R, Corbett CE. Clinical and immunopathological spectrum of American cutaneous leishmaniasis with special reference to the disease in Amazonian Brazil: a review. Mem Inst Oswaldo Cruz 2004; 99:239-51.
61. Alcaïs A, Abel L, David C, Torrez ME, Flandre P, Dedet JP. Evidence for a major gene controlling susceptibility to tegumentary leishmaniasis in a recently exposed Bolivian population. Am J Hum Genet 1997; 61:968-79.
62. Patz JA GA, McCarty JP, Hussein S, Confalonieri U, deWet N. Climate change and infectious diseases. In: McMichael AJ, Campbell-Lendrum DH, Corvalan CF, Ebi KL, Githeko AK, eds. Climate change and human health: risks and responses. Geneva: World Health Organization, 2003: 103-32.
63. Deborggraeve S, Claes F, Laurent T, et al. Molecular dipstick test for diagnosis of sleeping sickness. J Clin Microbiol 2006; 44:2884-9.
64. Kuboki N, Inoue N, Sakurai T, et al. Loop-mediated isothermal amplification for detection of African trypanosomes. J Clin Microbiol 2003; 41:5517-24.